PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth less than half of GNPX's 42.75%. David Dodd would verify if efficiency advantage is sustainable.
23.98%
G&A growth less than half of GNPX's 651.65%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses change of 7.46% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
15.26%
Operating expenses growth less than half of GNPX's 546.03%. David Dodd would verify sustainability.
15.26%
Total costs growth less than half of GNPX's 546.03%. David Dodd would verify sustainability.
-36.68%
Interest expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
7.46%
D&A change of 7.46% while GNPX maintains D&A. Bruce Berkowitz would investigate efficiency.
-50.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.14%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.01%
Share count reduction below 50% of GNPX's 5.88%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of GNPX's 6.02%. Michael Burry would check for concerns.